Shield Therapeutics plc

AIM:STX Rapporto sulle azioni

Cap. di mercato: UK£22.3m

Shield Therapeutics Crescita futura

Future criteri di controllo 2/6

Si prevede che Shield Therapeutics aumenterà gli utili e i ricavi rispettivamente del 84.6% e 46.9% all'anno, mentre si prevede che l'EPS crescerà del 104.1% all'anno.

Informazioni chiave

84.6%

Tasso di crescita degli utili

104.1%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili19.6%
Tasso di crescita dei ricavi46.9%
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento21 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Oct 30
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt

Oct 12
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt

Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story

Aug 01
Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story

Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now

Jun 13
Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now

Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost

May 22
Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost

Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

Mar 02
Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

May 06
What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

Mar 15
Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Jan 27
We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

Dec 15
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

Previsioni di crescita degli utili e dei ricavi

AIM:STX - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202672N/A-6-11
12/31/202554-8-7-41
12/31/202429-22-17-142
6/30/202421-36-23-21N/A
3/31/202417-35-32-29N/A
12/31/202313-33-40-37N/A
9/30/202310-40-35-33N/A
6/30/20237-47-30-28N/A
3/31/20236-49-28-25N/A
12/31/20225-50-25-23N/A
9/30/20225-39-27-24N/A
6/30/20224-30-31-27N/A
3/31/20223-29-29-26N/A
12/31/20212-27-27-25N/A
9/30/20212-22-21-20N/A
6/30/20213-18-16-16N/A
3/31/20219-11-9-9N/A
12/31/202014-4-2-2N/A
9/30/202013-3-1-1N/A
6/30/202011-200N/A
3/31/20206-6-4-3N/A
12/31/20191-12-7-5N/A
9/30/20198-4-11N/A
6/30/201915346N/A
3/31/201915003N/A
12/31/201815-2-40N/A
9/30/20188-13-14-9N/A
6/30/20181-24-24-19N/A
3/31/20181-26N/A-21N/A
12/31/20171-26N/A-22N/A
9/30/20171-24N/A-21N/A
6/30/20170-21N/A-19N/A
3/31/20170-19N/A-16N/A
12/31/20160-19N/A-13N/A
9/30/20160-12N/A-12N/A
6/30/20160-4N/A-10N/A
3/31/20160-19N/A-8N/A
12/31/2015N/A-35N/A-6N/A
9/30/20150-41N/A-5N/A
6/30/20150-49N/A-4N/A
3/31/20150-33N/A-5N/A
12/31/20140-20N/A-5N/A
12/31/20130-7N/A-5N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che STX rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che STX rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che STX rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di STX ( 46.9% all'anno) crescerà più rapidamente del mercato UK ( 3.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di STX ( 46.9% all'anno) crescerà più rapidamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di STX è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita